Breaking News

Kineticos Life Sciences Introduces Kinvard Bio

Aims to advance next-gen antibiotics in the fight against microbial resistance.

Author Image

By: Charlie Sternberg

Associate Editor

Kineticos Life Sciences has launched Kinvard Bio Inc., a new anti-infectives biotech company based on research that has been exclusively licensed from the Myers Lab in the Department of Chemistry and Chemical Biology at Harvard University and funded by the Kineticos AMR Accelerator Fund I (KAMRA I). KAMRA I is dedicated to combating antimicrobial resistance (AMR) by investing in, creating, and supporting companies that are developing disruptive solutions to address this critical public health...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters